AHR and cancer: Additionally, DL-1MT can down-regulates expression of paxillin-family proteins and promotes activation of AHR-driven responses in mesenchymal stromal cells (47) rising a pro-inflammatory signature that may augment the efficacy of cancer immunotherapies.